Introduction:
Resolution Therapeutics is facing a unique manufacturing challenge in developing macrophage therapy for end-stage liver disease. Macrophages are difficult to develop into medicine because they are terminally differentiated and do not multiply. The company needs to develop high-yield operations to overcome the challenge of losing cells as they differentiate and polarize. There is a critical interplay between processes and analytics in the manufacturing of macrophage therapy.
- Macrophages are being developed as a therapy for end-stage liver disease by manipulating their pro-restorative phenotype to reduce inflammation and scar tissue.
- Unlike T-cells, macrophages do not multiply and are lost as they differentiate and polarize into the desired phenotype.
- There is a need for high-yield operations to compensate for the loss of cells and ensure the quality of the medicine.
- The interplay between processes and analytics is crucial in understanding and maintaining the health of the cells.
- Resolution Therapeutics is working on building analytics into their processes, exploring automation and liquid handling technologies, and scaling up manufacturing for thousands of patients.
Conclusion:
Resolution Therapeutics is facing the challenge of manufacturing macrophages as a therapy for end-stage liver disease. They are developing high-yield operations and utilizing analytics to understand and maintain the health of the cells. Scaling up manufacturing and ensuring quality control are key considerations for supplying therapies to a large patient population.
